Explore the Agenda
8:00 am Registration & Morning Coffee
8:55 am Chair’s Opening Remarks
Establishing Translational Complex In Vitro Models to Advance Disease-Relevant Drug Discovery & Development
9:00 am Harnessing Patient-Derived Samples to Build Complex In Vitro Models for Precision Medicine Applications
- Utilizing patient-specific tissue sources to create models that accurately recapitulate disease biology for personalized drug development
- Showcasing how complex in vitro systems maintain in vivo characteristics to improve translational predictability and therapeutic relevance
- Advancing precision medicine strategies to enable targeted screening and accelerate development of individualized treatment approaches
9:30 am Enhanced Renal Toxicity Screening: Integrating EpiKidney™ with Live- Cell Analysis
- Drug-and chemical-induced nephrotoxicity often leads to compound failure during development and post-market drug withdrawals due to limitations in traditional animal study methods for predicting human responses
- EpiKidney™ is a 3D human-based in vitro platform that accurately predicts nephrotoxicity by offering a more physiological solution, enhancing the reliability of preclinical evaluations
- The platform integrates with Live-Cell Analysis for streamlined dose-range assessments, simplifying toxicity quantification and providing real-time insights into renal injury, thereby improving understanding of drug effects on human kidney tissue
10:00 am Leveraging Full-Thickness Skin Models to Enable Drug Screening for Dermatology Indications
- Establish clear morphological and molecular validation criteria to ensure that 3D skin models accurately mimic human skin tissue architecture
- Demonstrate consistent reproducibility across both dermal and epidermal layers, providing a robust foundation for reliable disease modeling
- Utilize validated 3D skin models to efficiently screen small molecule inhibitors, thereby accelerating the advancement of dermatology drug development programs
10:30 am Morning Refreshment & Speed Networking
As the 3D tissue modeling community is reunited, this valuable session will ensure you get the chance to reconnect with peers and make brand new connections! This structured networking opportunity will pair you with fellow attendees for several 3-minute introductions, ensuring you have the opportunity to meet and network with your academic and industry colleagues!
11:00 am Morning Refreshment Break
11:30 am Advancing Long-Acting Injectable Evaluation: Capturing Early Release Kinetics & Improved Translational Predictivity in Patient-centric CIVMs
- Assessing and Validating skin and eye CIVMs to recapitulate in vivo microenvironment
- Validated CIVMs Applied to Decipher the Drug's Early Release Behavior
- Cross-Species Data Translation for Enhanced Human Relevance
12:00 pm Advancing Microphysiological System Development to Bridge 2D & 3D Model Translation Gaps
- Comparing 2D versus 3D microphysiological systems to identify optimal validation approaches for preclinical development
- Evaluating neuronal and intestinal model systems to establish disease-specific benchmarking criteria and translational readiness
- Implementing barrier function and inflammation assessments to demonstrate physiological relevance in complex tissue models
Strategizing Model Development Timelines & Complexity to Optimize Research Efficiency & Pipeline Readiness
1:30 pm Roundtable Discussion: Balancing Model Complexity with Development Speed to Accelerate Viable Product Creation & Pipeline Progression
Join an interactive session where the audience is divided into small groups to explore key challenges in 3D tissue modeling. After the discussions, each group will share insights with the room so everyone can learn from their peers.
- Evaluating minimal viable model approaches to answer specific research questions without requiring overly complex system development
- Accelerating tissue interrogation timelines to compress disease progression responses that naturally occur over months or years
- Optimizing model customization workflows to reduce development time while maintaining predictive accuracy for competitive pipeline advancement
Moderator:
12:30 pm Lunch Break & Networking
Optimizing Complex In Vitro Model Selection & Validation Strategies to Enhance Drug Safety Assessment & Accelerate Development
2:15 pm Advancing Toxicity Testing Using Organoid & Organ-on-Chip Systems to Improve Drug Safety Predictions
- Implementing gut organoid models for screening diarrhea-inducing agents to enhance early-stage drug toxicity detection
- Comparing three-dimensional organoids versus organ-on-chip platforms to identify superior predictive screening methodologies
- Integrating live sensor readouts within organ-on-chip systems to provide real-time toxicity data for informed decision-making
2:45 pm Poster Competition
Witness some of the latest and greatest research in the 3D tissue modeling field by drug developers, academics, researchers, and platform developers in this spotlight poster session!
3:15 pm Afternoon Break
Strategizing Proactive Model Development Planning to Accelerate Research Readiness & Optimize Resource Allocation
3:45 pm Panel Discussion: Planning Ahead for CIVM Development to Ensure Models Are Ready for Critical Research Questions
- Anticipating future research needs early to reduce delays and accelerate model implementation when questions arise
- Evaluating existing platforms versus new models to minimize cost and time while maintaining scientific rigor
- Engaging senior leadership in proactive planning to align resources and timelines for complex model development
Moderator:
Enhancing Predictive Toxicity Assessment Through 3D In Vitro Systems to Accelerate Safe Drug Development
4:30 pm Validating Organ-on-Chip Models Across Platforms to Enhance Safety Predictions & Translational Accuracy
- Establishing project-specific validation criteria for organ-on-chip systems to assess translatability against animal studies and clinical outcomes
- Implementing multi-organ approaches including blood, liver, and skin-on-chip models to address diverse safety and efficacy questions
- Standardizing assay protocols across cell therapy and small molecule platforms to ensure reproducible safety hazard predictions